


Amendments to the Claims

1-10. (Cancelled)

11. (New) A compound of the formula (I)



where

(A) R¹ is substituted or unsubstituted oxazolyl, indolyl, pyrrolyl, pyrazolyl, triazinyl, 2-oxodihydrobenzo[d][1,3]oxazinyl, 4-oxodihydroimidazolyl, 5-oxo-4H-[1,2,4]triazinyl, 3-oxo-4H-benzo[1,4]thiazinyl, tetrahydroquinoxalinyl, 1,1,3-trioxodihydro-2H-1λ⁶-benzo[1,4]thiazinyl, 1-oxo-pyridyl, dihydro-2H-benzo[1,4]oxazinyl, 2-oxotetrahydrobenzo[e][1,4]diazepinyl, 2-oxodihydrobenzo[e][1,4]diazepinyl, 1H-pyrrolizinyl, phthalazinyl, 1-oxo-3H-isobenzofuranyl, 4-oxo-3H-thieno[2,3-d]pyrimidinyl, 3-oxo-4H-benzo[1,4]oxazinyl, [1,5]naphthyridyl, dihydro-2H-benzo[1,4]thiazinyl, 1,1-dioxodihydro-2H-benzo[1,4]thiazinyl, 2-oxo-1H-pyrido[2,3-b][1,4]oxazinyl, dihydro-1H-pyrido[2,3-b][1,4]oxazinyl, 1H-pyrrolo[2,3-b]pyridyl, benzooxazolyl, 2-oxobenzooxazolyl, 2-oxo-1,3-dihydroindolyl, 2,3-dihydroindolyl, indazolyl, benzofuranyl, dihydrobenzofuranyl, tetrahydropyranyl, 2-oxopiperidinyl or 2-oxoazepanyl; or

(B) R¹ is aryl which is substituted by at least one substituent selected from C₁₋₆-alkoxy-C₁₋₆-alkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl, C₀₋₆-alkylcarbonylamino, C₀₋₆-alkylcarbonylamino-C₁₋₆-alkyl, C₀₋₆-alkylcarbonylamino-C₁₋₆-alkoxy, (N-C₁₋₆-alkyl)-C₀₋₆-alkylcarbonylamino-C₁₋₆-alkyl, (N-C₁₋₆-alkyl)-C₀₋₆-alkylcarbonylamino-C₁₋₆-alkoxy, C₃₋₈-cycloalkylcarbonylamino-C₁₋₆-alkyl, C₃₋₈-cycloalkylcarbonylamino-C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkoxy-C₁₋₆-alkyl,

hydroxy-C₁₋₆-alkoxy-C₁₋₆-alkoxy, C₁₋₆-alkoxycarbonylamino-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonylamino-C₁₋₆-alkoxy, C₁₋₆-alkylaminocarbonylamino-C₁₋₆-alkyl, C₁₋₆-alkylaminocarbonylamino-C₁₋₆-alkoxy, C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkyl, C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy, C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy-C₁₋₆-alkyl, di-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkyl, di-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy, C₁₋₆-alkylcarbonyloxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyloxy-C₁₋₆-alkyl, C₁₋₆-alkylcarbonyloxy-C₁₋₆-alkoxy, cyano-C₁₋₆-alkyl, cyano-C₁₋₆-alkoxy, C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl-C₁₋₆-alkoxy, C₁₋₆-alkylsulphonylamino-C₁₋₆-alkyl, C₁₋₆-alkylsulphonylamino-C₁₋₆-alkoxy, (N-C₁₋₆-alkyl)-C₁₋₆-alkylsulphonylamino-C₁₋₆-alkyl, (N-C₁₋₆-alkyl)-C₁₋₆-alkylsulphonylamino-C₁₋₆-alkoxy, amino-C₁₋₆-alkyl, amino-C₁₋₆-alkoxy, C₁₋₆-alkylamino-C₁₋₆-alkyl, C₁₋₆-alkylamino-C₁₋₆-alkoxy, di-C₁₋₆-alkylamino-C₁₋₆-alkyl, di-C₁₋₆-alkylamino-C₁₋₆-alkoxy, C₁₋₆-alkylsulphonyl-C₁₋₆-alkyl, C₁₋₆-alkylsulphonyl-C₁₋₆-alkoxy, carboxy-C₁₋₆-alkyl, carboxy-C₁₋₆-alkoxy, carboxy-C₁₋₆-alkoxy-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkylcarbonyl, acyl-C₁₋₆-alkoxy-C₁₋₆-alkyl, (N-C₁₋₆-alkyl)-C₁₋₆-alkoxycarbonylamino, (N-hydroxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkyl, (N-hydroxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy, (N-hydroxy)aminocarbonyl-C₁₋₆-alkyl, (N-hydroxy)aminocarbonyl-C₁₋₆-alkoxy, C₁₋₆-alkoxyaminocarbonyl-C₁₋₆-alkyl, C₁₋₆-alkoxyaminocarbonyl-C₁₋₆-alkoxy, (N-C₁₋₆-alkoxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkyl, (N-C₁₋₆-alkoxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy, (N-acyl)-C₁₋₆-alkoxy-C₁₋₆-alkylamino, C₁₋₆-alkoxy-C₁₋₆-alkylcarbamoyl, (N-C₁₋₆-alkyl)-C₁₋₆-alkoxy-C₁₋₆-alkylcarbamoyl, C₁₋₆-alkoxy-C₁₋₆-alkylcarbonyl, C₁₋₆-alkoxy-C₁₋₆-alkylcarbonylamino, (N-C₁₋₆-alkyl)-C₁₋₆-alkoxy-C₁₋₆-alkylcarbonyl, carbamoyl-C₁₋₆-alkyl, carbamoyl-C₁₋₆-alkoxy, C₁₋₆-alkylcarbamoyl, di-C₁₋₆-alkylcarbamoyl, C₁₋₆-alkylsulphonyl, C₁₋₆-alkylamidinyl, acetamidinyl-C₁₋₆-alkyl, O-methyloximyl-C₁₋₆-alkyl and O,N-dimethylhydroxylamino-C₁₋₆-alkyl; or

(C) R¹ in formula (I) is aryl or heterocyclyl which is substituted by at least one substituent selected from [1,2,4]-triazol-1-ylalkyl, [1,2,4]-triazol-1-ylalkoxy, [1,2,4]-triazol-4-ylalkyl, [1,2,4]-triazol-4-ylalkoxy, [1,2,4]-oxadiazol-5-ylalkyl, [1,2,4]-oxadiazol-5-ylalkoxy, 3-methyl-[1,2,4]-oxadiazol-5-ylalkyl, 3-methyl-

[1,2,4]-oxadiazol-5-ylalkoxy, 5-methyl-[1,2,4]-oxadiazol-3-ylalkyl, 5-methyl-[1,2,4]-oxadiazol-3-ylalkoxy, tetrazol-1-ylalkyl, tetrazol-1-ylalkoxy, tetrazol-2-ylalkyl, tetrazol-2-ylalkoxy, tetrazol-5-ylalkyl, tetrazol-5-ylalkoxy, 5-methyltetrazol-1-ylalkyl, 5-methyltetrazol-1-ylalkoxy, thiazol-4-ylalkyl, thiazol-4-ylalkoxy, oxazol-4-ylalkyl, oxazol-4-ylalkoxy, 2-oxopyrrolidinylalkyl, 2-oxopyrrolidinylalkoxy, imidazolylalkyl, imidazolylalkoxy, 2-methylimidazolylalkyl, 2-methylimidazolylalkoxy, dioxolanyl, dioxanyl, dithiolanyl, dithianyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrrolyl, 4-methylpiperazinyl, morpholinyl, thiomorpholinyl, 2-hydroxymethylpyrrolidinyl, 3-hydroxypyrrrolidinyl, 3,4-dihydroxypyrrrolidinyl, 3-acetamidomethylpyrrolidinyl, 3-C₁₋₆-alkoxy-C₁₋₆-alkylpyrrolidinyl, 4-hydroxypiperidinyl, 4-oxopiperidinyl, 3,5-dimethylmorpholinyl, 4,4-dioxothiomorpholinyl, 4-oxothiomorpholinyl, 2,6-dimethylmorpholinyl, 2-oxoimidazolidinyl, 2-oxooxazolidinyl, 2-oxopyrrolidinyl, 2-oxo-[1,3]oxazinyl, 2-oxotetrahydropyrimidinyl, 2-oxooxazolidinyl-C₁₋₆-alkyl, 2-oxooxazolidinyl-C₁₋₆-alkoxy, 1-C₁₋₆-alkoxy-C₁₋₆-alkylimidazol-2-yl, 1-C₁₋₆-alkoxy-C₁₋₆-alkyltetrazol-5-yl, 5-C₁₋₆-alkoxy-C₁₋₆-alkyltetrazol-1-yl and 2-C₁₋₆-alkoxy-C₁₋₆-alkyl-4-oxoimidazol-1-yl; or

(D) R¹ is aryl or heterocyclyl if n is 0 and X is -O-CH-R¹¹-CO-NR⁹-, or if n and m are each 0 and X is -O-CH-R¹¹- and R² is phenyl substituted by C₁₋₆-alkoxybenzyloxy-C₁₋₆-alkoxy; or

(E) R¹ is aryl or heterocyclyl if n is 1 and Z is -alk-NR⁹-, where alk is C₁₋₆-alkylene; or

(F) R¹ is aryl or heterocyclyl when R² is tetrazolyl or imidazolyl which may be substituted by 1-3 halogen, hydroxyl, cyano, trifluoromethyl, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkyl, cyano-C₁₋₆-alkyl, carboxy-C₁₋₆-alkyl, C₁₋₆-alkanoyloxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyloxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl, or C₁₋₆-alkoxy groups, or a C₁₋₆-alkylenedioxy group, and/or may be substituted by an L1-T1-L2-T2-L3-T3-L4-T4-L5-U radical;

R² is phenyl substituted by 1-3 halogen, hydroxyl, cyano, trifluoromethyl, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkyl, cyano-C₁₋₆-alkyl, carboxy-C₁₋

C_{1-6} -alkyl, C_{1-6} -alkanoyloxy- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyloxy- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyl, or C_{1-6} -alkoxy groups, or a C_{1-6} -alkylenedioxy group, and/or by an L1-T1-L2-T2-L3-T3-L4-T4-L5-U radical;

L1, L2, L3, L4 and L5 are each independently a bond, C_{1-8} -alkylene, C_{2-8} -alkenylene or C_{2-8} -alkynylene, or are absent;

T1, T2, T3 and T4 are each independently

- (a) a bond, or are absent, or are one of the groups
- (b) $-\text{CH}(\text{OH})-$
- (c) $-\text{CH}(\text{OR}^6)-$
- (d) $-\text{CH}(\text{NR}^5\text{R}^6)-$
- (e) $-\text{CO}-$
- (f) $-\text{CR}^7\text{R}^8-$
- (g) $-\text{O}-$ or $-\text{NR}^6-$
- (h) $-\text{S}(\text{O})_{0-2}-$
- (I) $-\text{SO}_2\text{NR}^6-$
- (j) $-\text{NR}^6\text{SO}_2-$
- (k) $-\text{CONR}^6-$
- (l) $-\text{NR}^6\text{CO}-$
- (m) $-\text{O-CO-}$
- (n) $-\text{CO-O-}$
- (o) $-\text{O-CO-O-}$
- (p) $-\text{O-CO-NR}^6-$
- (q) $-\text{N}(\text{R}^6)-\text{CO-N}(\text{R}^6)-$
- (r) $-\text{N}(\text{R}^6)-\text{CO-O-}$
- (s) pyrrolidinylene, piperidinylene or piperazinylene
- (t) $-\text{C}(\text{R}^{11})(\text{R}^{12})-$,

where the bonds starting from (b)-(t) lead to a saturated or aromatic carbon atom of the adjacent group if the bond starts from a heteroatom, and where not more than two (b)-(f) groups, three (g)-(h) groups and one (i)-(t) group are present;

R^3 is hydrogen;

R⁴ is hydrogen;

R⁵ and R⁶ are each independently hydrogen, C₁₋₆-alkyl, C₂₋₆-alkenyl, aryl-C₁₋₆-alkyl or acyl, or, together with the nitrogen atom to which they are bonded, are a 5- or 6-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or a -SO- or -SO₂- group, and the additional nitrogen atom may optionally be substituted by C₁₋₆-alkyl radicals;

R⁷ and R⁸, together with the carbon atom to which they are bonded, are a 3-7-membered ring which may contain one or two -O- or -S- atoms or -SO- or -SO₂- groups;

R⁹ is hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkyl, acyl or arylalkyl;

R¹⁰ is carboxyalkyl, alkoxy carbonylalkyl, alkyl or hydrogen;

R¹¹ is hydrogen or C₁₋₆-alkyl;

R¹² is hydrogen or C₁₋₆-alkyl;

U is hydrogen, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, cyano, optionally substituted C₃₋₈-cycloalkyl, aryl, or heterocyclyl;

Q is absent;

X is a bond, oxygen or sulphur, or is a >CH-R¹¹, >CHOR⁹, -O-CO-, >CO, >C=NOR¹⁰, -O-CHR¹¹- or -O-CHR¹¹-CO-NR⁹- group and the bond starting from an oxygen or sulphur atom leads to a saturated carbon atom of the Z group or to R¹;

W is oxygen or sulphur;

Z is C₁₋₆-alkylene, C₂₋₆-alkenylene, hydroxy-C₁₋₆-alkylidene, -O-, -S-, -O-alk-, -S-alk-, -alk-O-, -alk-S- or -alk-NR⁹-, where alk is C₁₋₆-alkylene; and where


- (a) if Z is -O- or -S-, X is >CH-R¹¹ and either R² contains an L1-T1-L2-T2-L3-T3-L4-T4-L5-U substituent or R⁴ is a substituent other than hydrogen as defined above;
- (b) if Z is -O-alk- or -S-alk-, X is >CH-R¹¹; and
- (c) if X is a bond, Z is C₂₋₆-alkenylene, -alk-O- or -alk-S-,

n is 0 or 1;

m is 0;

or a pharmaceutically acceptable salt thereof.

12. (New) A compound according to Claim 11 of the formula (IA)



where R^1 , R^2 , R^3 , R^4 , Q , W , X , Z , n and m are each as defined for the compounds of the formulae (I) according to Claim 11.

13. (New) A compound according to Claim 11 or 12 where

R^1 is as defined for (A), (B), (C), (D), (E) or (F), more preferably as specified for (A), (B), (C) or (D); R^2 is phenyl substituted by halogen, hydroxyl, cyano, trifluoromethyl, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, C_{1-6} -alkoxy- C_{1-6} -alkyl, cyano- C_{1-6} -alkyl, carboxy- C_{1-6} -alkyl, C_{1-6} -alkanoyloxy- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyloxy- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyl, C_{1-6} -alkoxy, C_{1-6} -alkylenedioxy, or by an L_1 - T_1 - L_2 - T_2 - L_3 - T_3 - L_4 - T_4 - L_5 - U radical; or naphthyl or acenaphthyl;

L_1 , L_2 , L_3 , L_4 and L_5 are each independently a bond, C_{1-8} -alkylene, C_{2-8} -alkenylene or C_{2-8} -alkynylene, or are absent;

T_1 , T_2 , T_3 and T_4 are each independently

- (a) a bond, or are absent, or are one of the groups
- (b) $-\text{CH}(\text{OH})-$
- (c) $-\text{CH}(\text{OR}^6)-$
- (d) $-\text{CH}(\text{NR}^5\text{R}^6)-$
- (e) $-\text{CO}-$
- (f) $-\text{CR}^7\text{R}^8-$
- (g) $-\text{O}-$ or $-\text{NR}^6-$
- (h) $-\text{S}(\text{O})_{0-2}-$

- (I) $-\text{SO}_2\text{NR}^6-$
- (j) $-\text{NR}^6\text{SO}_2-$
- (k) $-\text{CONR}^6-$
- (l) $-\text{NR}^6\text{CO}-$
- (m) $-\text{O-CO-}$
- (n) $-\text{CO-O-}$
- (o) $-\text{O-CO-O-}$
- (p) $-\text{O-CO-NR}^6-$
- (q) $-\text{N}(\text{R}^6)-\text{CO-N}(\text{R}^6)-$
- (r) $-\text{N}(\text{R}^6)-\text{CO-O-}$
- (s) pyrrolidinylene, piperidinylene or piperazinylene
- (t) $-\text{C}(\text{R}^{11})(\text{R}^{12})-$,

where the bonds starting from (b)-(t) lead to a saturated or aromatic carbon atom of the adjacent group if the bond starts from a heteroatom, and where not more than two (b)-(f) groups, three (g)-(h) groups and one (i)-(t) group are present;

R^3 is hydrogen;

R^4 is hydrogen;

R^5 and R^6 are each independently hydrogen, C_{1-6} -alkyl or acyl, or, together with the nitrogen atom to which they are bonded, are a 5- or 6-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom;

R^7 and R^8 , together with the carbon atom to which they are bonded, are a 3-7-membered ring which may contain one or two $-\text{O-}$ or $-\text{S-}$ atoms;

R^9 is hydrogen, C_{1-6} -alkyl, acyl or arylalkyl;

U is hydrogen, C_{1-6} -alkyl, C_{3-8} -cycloalkyl, cyano, aryl or heterocyclyl;

Q is absent;

X is oxygen, sulphur or a $>\text{CH}_2$, $>\text{CHOR}^9$, $-\text{O-CO-}$, $>\text{CO}$ or $-\text{O-CH-R}^{11}-\text{CO-NR}^9-$ group;

W is oxygen or sulphur if R^3 is hydrogen;

Z is C_{1-6} -alkylene or $-\text{alk-O-}$;

n is 0 or 1;

m is 0;

or a pharmaceutically acceptable salt thereof.

14. (New) A compound according to Claim 11, wherein R¹ is 3-C₁₋₆-alkylindolyl, benzofuranyl, 4H-benzo[1,4]oxazin-3-onyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, 3,4-dihydro-2H-benzo[1,4]thiazinyl, 3,3-di-C₁₋₆-alkyl-1,3-dihydroindol-2-onyl, 3,3-di-C₁₋₆-alkyl-1,3-dihydroindolyl, indolyl, 3-methylindolyl and spiro[cyclopropane-1,3']-2,3-dihydro-1H-indolyl, each of which may in particular be substituted by at least one substituent selected from C₁₋₆-alkoxy-C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, N-acetyl-C₁₋₆-alkoxy-C₁₋₆-alkylamino, C₁₋₆-alkanoylamido-C₁₋₆-alkyl, N-C₁₋₆-alkyl-C₁₋₆-alkanoylamido-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkoxy-C₁₋₆-alkyl, triazol-1-yl-C₁₋₆-alkyl, tetrazol-1-yl-C₁₋₆-alkyl, tetrazol-2-yl-C₁₋₆-alkyl, tetrazol-5-yl-C₁₋₆-alkyl, C₁₋₆-alkoxycarboxyl-C₁₋₆-alkyl, pyrrolidinonyl-C₁₋₆-alkyl, imidazolyl-C₁₋₆-alkyl, cyano-C₁₋₆-alkyl, carboxy-C₁₋₆-alkyl, carboxy-C₁₋₆-alkoxy, C₁₋₆-alkoxycarbonyl-C₀₋₆-alkyl, C₁₋₆-alkylsulphonamidyl-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkanoylamido, C₁₋₆-alkoxy-C₁₋₆-alkanoylamido-C₁₋₆-alkyl, N-(C₁₋₆-alkyl)-C₁₋₆-alkoxy-C₁₋₆-alkanoylamido, N-C₁₋₆-alkylcarbamoyl-C₁₋₆-alkyl, C₃₋₈-cycloalkanoylamido-C₁₋₆-alkyl, C₁₋₆-alkylaminocarbonylamino-C₁₋₆-alkyl, C₁₋₆-alkanoylamidomethylpyrrolidinyl, N-(C₁₋₆-alkoxy-C₁₋₆-alkyl)carbamoyl, N-(C₁₋₆-alkoxy-C₁₋₆-alkyl)-N-(C₁₋₆-alkyl)carbamoyl, N-(C₁₋₆-alkoxy-C₁₋₆-alkyl)imidazol-2-yl, hydroxy-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkoxy, hydroxy-C₁₋₆-alkoxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonylamido-C₁₋₆-alkyl, amino-C₁₋₆-alkyl and C₁₋₆-alkylamino-C₁₋₆-alkyl.

15. (New) A compound according to Claim 11, wherein R² is phenyl substituted by C₁₋₆-alkoxybenzyloxy-C₁₋₆-alkoxy, C₁₋₆-alkoxyphenyl-C₁₋₆-alkoxy-C₁₋₆-alkoxy, C₁₋₆-alkylphenoxy-C₁₋₆-alkoxy, halobenzyloxy-C₁₋₆-alkoxy, halophenoxy-C₁₋₆-alkoxy, halophenoxy-C₁₋₆-alkoxy-C₁₋₆-alkyl, N-(halophenyl)pyrrolidin-3-yloxy or indol-4-yloxy-C₁₋₆-alkyl.

16. (New) A compound according to Claim 11, wherein X is oxygen, -O-CH₂-CO-NH-, -O-CH₂-CO-N(CH₃)- or -O-CH(CH₃)-CO-NH-.

17. (New) A compound according to Claim 11, wherein Z is methylene, -(CH₂)₂-O- or -CH(CH₃)-.

18. (New) The compound 6-chloromethyl-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one or 6-hydroxymethyl-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one.

19. (New) A pharmaceutical preparation comprising a compound of the formula (I) or (IA) or salt according to Claim 11 or 12, and a pharmaceutically inert excipient.

20. (New) A method for treatment or prevention of hypertension, heart failure, glaucoma, cardiac infarction, kidney failure or restenoses, which comprises administering an effective amount of a compound or salt according to Claim 11 or 12 to a patient in need thereof.

21. (New) A method for the preparation of a medicament, which comprises admixing a compound or salt according to Claim 11 or 12 with a pharmaceutically inert excipient.

22. (New) A method according to Claim 21, wherein the medicament is a medicament for the treatment or prevention of hypertension, heart failure, glaucoma, cardiac infarction, kidney failure or restenoses.